iShares MSCI Germany (DAX) vs Novartis AG — how do they compare? iShares MSCI Germany (DAX) trades at $41.98 (market cap $1.42B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is far larger — about 189.1× iShares MSCI Germany (DAX)'s market cap, and Novartis AG pays a 3.31% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 56 Days and Novartis AG for 82 Days on average.
| EWG | NVS | |
|---|---|---|
Market Cap | $1.42B | $268.57B |
Volume | 1,110,573 | 1,532,573 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $168.62 |
52-Week Low | $38.08 | $121.80 |
Typical Hold Time | 56 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.91, down 1.4% with a bearish technical outlook showing 19 sell signals versus 1 buy. The stock faces resistance at $41 with support at $40. Technical indicators show oversold conditions with RSI at 25.94, but moving averages and oscillators remain bearish. Recent European market sentiment is mixed with ECB rate hikes and energy price concerns affecting regional equities.
Investment outlook remains cautious given the bearish technical signals and macroeconomic pressures from ECB tightening. The stock's proximity to support levels suggests potential for near-term stabilization, but sustained recovery requires improved fundamental performance and easing of European economic concerns.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →